{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:18:45Z","timestamp":1782973125109,"version":"3.54.5"},"reference-count":31,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2011]]},"DOI":"10.2133\/dmpk.dmpk-10-rg-113","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T06:13:06Z","timestamp":1299219186000},"page":"280-287","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacokinetics of Bosentan in Routinely Treated Japanese Pediatric Patients with Pulmonary Arterial Hypertension"],"prefix":"10.2133","volume":"26","author":[{"given":"Masato","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukiko","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(25)22357-6","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0020","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/bdd.671","article-title":"Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction","volume":"30","author":"Horiuchi","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","article-title":"Genetic analysis of CYP2C9 polymorphism in a Japanese population","volume":"7","author":"Nasu","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"Suppl. 2","key":"10.2133\/dmpk.DMPK-10-RG-113_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C9 gene","volume":"33","author":"Schwarz","year":"2003","journal-title":"Eur. J. Clin. Invest."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0040","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism","volume":"62","author":"Lin","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clpt.2005.11.003","article-title":"Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics","volume":"79","author":"Katz","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1124\/jpet.302.2.804","article-title":"Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis","volume":"302","author":"Nozawa","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2133\/dmpk.23.406","article-title":"Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure","volume":"23","author":"Tsujimoto","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FPC.0b013e32831bd98c","article-title":"Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response","volume":"19","author":"Mougey","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2133\/dmpk.21.165","article-title":"Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects","volume":"21","author":"Tsujimoto","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/14622416.9.1.19","article-title":"Global analysis of genetic variation in SLCO1B1","volume":"9","author":"Pasanen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0090","series-title":"NONMEM Users Guides: NONMEM Project Group","author":"Beal","year":"1992"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00008571-200308000-00004","article-title":"Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups","volume":"13","author":"Lee","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2009.03532.x","article-title":"Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study","volume":"68","author":"Beghetti","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2133\/dmpk.23.128","article-title":"Additional notes on clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance","volume":"23","author":"Takaai","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0110","first-page":"303","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters","volume":"11","author":"Sheiner","year":"1983","journal-title":"III. Monoexponential model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/00000542-199210000-00006","article-title":"Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin","volume":"77","author":"Cahalan","year":"1992","journal-title":"Anesthesiology"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1248\/bpb.29.772","article-title":"Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers","volume":"29","author":"Honda","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01061662","article-title":"A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam","volume":"19","author":"Maitre","year":"1991","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.drudis.2008.11.004","article-title":"Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling","volume":"14","author":"Ince","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u00afdrug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0140","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/01.CCM.0000054905.39382.58","article-title":"Research in children","volume":"31","author":"Burns","year":"2003","journal-title":"Crit. Care Med."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jmg.2008.062703","article-title":"A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension","volume":"46","author":"Shintani","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.2133\/dmpk.DMPK-10-RG-113_bb0155","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:15:40Z","timestamp":1740982540000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715305826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"alternative-id":["S1347436715305826"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rg-113","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}